Tailored Liposomal Nanocarriers for Precision Breast Cancer Therapy
Abstract
Breast cancer remains one of the most frequently diagnosed malignancies worldwide and continues to represent a major public health concern despite substantial advances in diagnostic and therapeutic strategies. Conventional chemotherapy, although effective in many cases, is often associated with non-specific drug distribution, severe systemic toxicity, limited bioavailability, and the development of multidrug resistance. These limitations significantly compromise therapeutic outcomes and patient quality of life. Liposome-based drug delivery systems have developed as a highly promising nanotechnological approach to address these challenges by improving drug solubility, stability, circulation time, and tumor selectivity. Through rational design and surface functionalization, liposomes can be engineered to achieve passive and active targeting, controlled drug release, and reduced off-target effects. This review provides an expanded and original discussion of liposomal nanocarriers developed for targeted breast cancer therapy, covering formulation strategies, classification, targeting mechanisms, stimuli-responsive systems, clinical applications, current challenges, and future perspectives.
Keywords: Liposomal nanocarriers; Breast cancer therapy; Targeted drug delivery; Nanomedicine; Stimuli-responsive systems; Precision oncology
Keywords:
Liposomal nanocarriers, Breast cancer therapy, Targeted drug deliveryDOI
https://doi.org/10.22270/jddt.v16i2.7544References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2021; 71:209-249 https://doi.org/10.3322/caac.21660 PMid:33538338
2. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, Cronin KA, US incidence of breast cancer subtypes defined by joint hormone-receptor and HER2 status, J Natl Cancer Inst, 2014; 106 https://doi.org/10.1093/jnci/dju055 PMid:24777111 PMCid:PMC4580552
3. Akinyemiju TF, Pisu M, Waterbor JW, Altekruse SF, Socioeconomic status and incidence of breast cancer by hormone receptor subtype, SpringerPlus, 2015; 4:1-8 https://doi.org/10.1186/s40064-015-1282-2 PMid:26405628 PMCid:PMC4573746
4. Momenimovahed Z, Salehiniya H, Epidemiological characteristics of and risk factors for breast cancer in the world, Breast Cancer, 2019; 11:151-164 https://doi.org/10.2147/BCTT.S176070 PMCid:PMC6462164
5. Azamjah N, Soltan-Zadeh Y, Zayeri F, Global trend of breast cancer mortality rate: a 25-year study, Asian Pac J Cancer Prev, 2019; 20:2015-2020 https://doi.org/10.31557/APJCP.2019.20.7.2015 PMid:31350959 PMCid:PMC6745227
6. Akram M, Iqbal M, Daniyal M, Khan AU, Awareness and current knowledge of breast cancer, Biol Res, 2017; 50:33 https://doi.org/10.1186/s40659-017-0140-9 PMid:28969709 PMCid:PMC5625777
7. Núnez C, Capelo JL, Igrejas G, Alfonso A, Botana LM, Lodeiro C, An overview of the effective combination therapies for the treatment of breast cancer, Biomaterials, 2016; 97:34-50 https://doi.org/10.1016/j.biomaterials.2016.04.027 PMid:27162073
8. Trevisi E, La Salvia A, Daniele L, Brizzi MP, De Rosa G, Scagliotti GV, Di Maio M, Neuroendocrine breast carcinoma: a rare but challenging entity, Med Oncol, 2020; 37:70 https://doi.org/10.1007/s12032-020-01396-4 PMid:32712767 PMCid:PMC7382662
9. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, Graf S, Ha G, Haffari G, Bashashati A, Russell R, McKinney S, Aparicio S, Brenton JD, Ellis I, Huntsman D, Pinder S, Murphy L, Bardwell H, Ding Z, Jones L, Liu B, Papatheodorou I, Sammut SJ, Wishart G, Chia S, Gelmon K, Speers C, Watson P, Blamey R, Green A, MacMillan D, Rakha E, Gillett C, Grigoriadis A, De Rinaldis E, Tutt A, Parisien M, Troup S, Chan D, Fielding C, Maia AT, McGuire S, Osborne M, Sayalero SM, Spiteri I, Hadfield J, Bell L, Chow K, Gale N, Kovalik M, Ng Y, Prentice L, Tavaré S, Markowetz F, Langerød A, Provenzano E, Purushotham A, Børresen-Dale AL, Caldas C, The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups, Nature, 2012; 486:346-352 https://doi.org/10.1038/nature10983 PMid:22522925 PMCid:PMC3440846
10. Leong ASY, Zhuang Z, The changing role of pathology in breast cancer diagnosis and treatment, Pathobiology, 2011; 78:99-114 https://doi.org/10.1159/000292644 PMid:21677473 PMCid:PMC3128144
11. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ, Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011, Ann Oncol, 2011; 22:1736-1747 https://doi.org/10.1093/annonc/mdr304 PMid:21709140 PMCid:PMC3144634
12. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM, Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Res, 2010; 12:1-18 https://doi.org/10.1186/bcr2635 PMid:20813035 PMCid:PMC3096954
13. Prat A, Pineda E, Adamo B, Galvan P, Fernández A, Gaba L, Díez M, Viladot M, Arance A, Munoz M, Clinical implications of the intrinsic molecular subtypes of breast cancer, Breast, 2015; 24:S26-S35 https://doi.org/10.1016/j.breast.2015.07.008 PMid:26253814
14. Narod SA, BRCA mutations in the management of breast cancer: the state of the art, Nat Rev Clin Oncol, 2010; 7:702-707 https://doi.org/10.1038/nrclinonc.2010.166 PMid:20956982
15. Onitilo AA, Engel JM, Greenlee RT, Mukesh BN, Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival, Clin Med Res, 2009; 7:4-13 https://doi.org/10.3121/cmr.2009.825 PMid:19574486 PMCid:PMC2705275
16. Malorni L, Shetty PB, De Angelis C, Hilsenbeck S, Rimawi MF, Elledge R, Osborne CK, De Placido S, Arpino G, Clinical and biologic features of triple-negative breast cancers in a large cohort of patients with long-term follow-up, Breast Cancer Res Treat, 2012; 136:795-804 https://doi.org/10.1007/s10549-012-2315-y PMid:23124476 PMCid:PMC3513514
17. Moo TA, Sanford R, Dang C, Morrow M, Overview of breast cancer therapy, Pet Clin, 2018; 13:339-354 https://doi.org/10.1016/j.cpet.2018.02.006 PMid:30100074 PMCid:PMC6092031
18. Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ, Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype, Breast Cancer Res Treat, 2012; 133:831-841 https://doi.org/10.1007/s10549-011-1891-6 PMid:22147079
19. Denduluri N, Chavez-MacGregor M, Telli ML, Eisen A, Graff SL, Hassett MJ, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Somerfield MR, Trudeau ME, Wolff AC, Giordano SH, Selection of optimal adjuvant chemotherapy and targeted therapy for early breast cancer: ASCO clinical practice guideline focused update, J Clin Oncol, 2018; 36:2433-2443 https://doi.org/10.1200/JCO.2018.78.8604 PMid:29787356
20. Goldstein SR, Siddhanti S, Ciaccia AV, Plouffe L, A pharmacological review of selective oestrogen receptor modulators, Hum Reprod Update, 2000; 6:212-224 https://doi.org/10.1093/humupd/6.3.212 PMid:10874566
21. Smith IE, Dowsett M, Aromatase inhibitors in breast cancer, N Engl J Med, 2003; 348:2431-2442 https://doi.org/10.1056/NEJMra023246 PMid:12802030
22. Ali S, Mondal N, Choudhry H, Rasool M, Pushparaj PN, Khan MA, Mahfooz M, Sami GA, Jarullah J, Ali A, Jamal MS, Current management strategies in breast cancer by targeting key altered molecular players, Front Oncol, 2016; 6 https://doi.org/10.3389/fonc.2016.00045
23. Alavi M, Hamidi M, Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles, Drug Metab Pers Ther, 2019; 34 https://doi.org/10.1515/dmpt-2018-0032 PMid:30707682
24. Mokhatri-Hesari P, Montazeri A, Health-related quality of life in breast cancer patients: review of reviews from 2008 to 2018, Health Qual Life Outcomes, 2020; 18:1-25 https://doi.org/10.1186/s12955-020-01591-x PMid:33046106 PMCid:PMC7552560
25. Teixeira S, Carvalho MA, Castanheira EMS, Functionalized liposome and albumin-based systems as carriers for poorly water-soluble anticancer drugs: an updated review, Biomedicines, 2022; 10:486 https://doi.org/10.3390/biomedicines10020486 PMid:35203695 PMCid:PMC8962385
26. Schleicher SM, Bach PB, Matsoukas K, Korenstein D, Medication overuse in oncology: current trends and future implications for patients and society, Lancet Oncol, 2018; 19:e200-e208 https://doi.org/10.1016/S1470-2045(18)30099-8 PMid:29611528
27. Wadhwani N, Jatoi I, Overuse of neo-adjuvant chemotherapy for primary breast cancer, Indian J Surg Oncol, 2020; 11:12-14 https://doi.org/10.1007/s13193-019-01002-8 PMid:32205961 PMCid:PMC7064655
28. Li YJ, Lei YH, Yao N, Wang CR, Hu N, Ye WC, Zhang DM, Chen ZS, Autophagy and multidrug resistance in cancer, Chin J Cancer, 2017; 36:52 https://doi.org/10.1186/s40880-017-0219-2 PMid:28646911 PMCid:PMC5482965
29. Singh SK, Singh S, Wlillard J, Singh R, Drug delivery approaches for breast cancer, Int J Nanomed, 2017; 12:6205-6218 https://doi.org/10.2147/IJN.S140325 PMid:28883730 PMCid:PMC5576701
30. Assaraf YG, Brozovic A, Gonçalves AC, Jurkovicova D, Line A, Machuqueiro M, Saponara S, Sarmento-Ribeiro AB, Xavier CPR, Vasconcelos MH, The multi-factorial nature of clinical multidrug resistance in cancer, Drug Resist Updates, 2019; 46:100645 https://doi.org/10.1016/j.drup.2019.100645 PMid:31585396
31. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KLR, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KL, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, Membrane transporters in drug development, Nat Rev Drug Discov, 2010; 9:215-236 https://doi.org/10.1038/nrd3028 PMid:20190787 PMCid:PMC3326076
32. Tacar O, Sriamornsak P, Dass CR, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems, J Pharm Pharmacol, 2013; 65:157-170 https://doi.org/10.1111/j.2042-7158.2012.01567.x PMid:23278683
33. He H, Liu C, Wu Y, Zhang X, Fan J, Cao Y, A multiscale physiologically-based pharmacokinetic model for doxorubicin to explore its mechanisms of cytotoxicity and cardiotoxicity in human physiological contexts, Pharm Res, 2018; 35:1-10 https://doi.org/10.1007/s11095-018-2456-8 PMid:29987398 PMCid:PMC6533104
34. Zhang N, Shu G, Qiao E, Xu X, Shen L, Lu C, Chen W, Fang S, Yang Y, Song J, Zhao Z, Tu J, Xu M, Chen M, Du Y, Ji J, DNA-functionalized liposomes in vivo fusion for NIR-II/MRI guided pretargeted ferroptosis therapy of metastatic breast cancer, ACS Appl Mater Interfaces, 2022; 14:20603-20615 https://doi.org/10.1021/acsami.2c01105 PMid:35476429
35. Gottesman MM, Fojo T, Bates SE, Multidrug resistance in cancer: role of ATP-dependent transporters, Nat Rev Cancer, 2002; 2:48-58 https://doi.org/10.1038/nrc706 PMid:11902585
36. Mao Z, Shen K, Zhu L, Xu M, Yu F, Xue D, Li H, Xue C, Comparisons of cardiotoxicity and efficacy of anthracycline-based therapies in breast cancer: a network meta-analysis of randomized clinical trials, Oncol Res Treat, 2019; 42:405-413 https://doi.org/10.1159/000500204 PMid:31104059
37. Caswell-Jin JL, Plevritis SK, Tian L, Cadham CJ, Xu C, Stout NK, Sledge GW, Mandelblatt JS, Kurian AW, Change in Survival in Metastatic Breast Cancer with Treatment Advances: Meta-Analysis and Systematic Review, JNCI Cancer Spectr, 2018; 2 https://doi.org/10.1093/jncics/pky062 PMid:30627694 PMCid:PMC6305243
38. Cardoso F, Spence D, Mertz S, Corneliussen-James D, Sabelko K, Gralow J, Cardoso MJ, Peccatori F, Paonessa D, Benares A, Sakurai N, Beishon M, Barker SJ, Mayer M, Global analysis of advanced/metastatic breast cancer: decade report (2005-2015), Breast, 2018; 39:131-138 https://doi.org/10.1016/j.breast.2018.03.002 PMid:29679849
39. Li A, Schleicher SM, Andre F, Mitri ZI, Genomic alteration in metastatic breast cancer and its treatment, Am Soc Clin Oncol Educ Book, 2020; 1-14 https://doi.org/10.1200/EDBK_280463 PMid:32213086
40. Liu R, Zhou J, Yang S, Zhang Z, Efficacy and safety of pegylated liposomal doxorubicin-based chemotherapy of AIDS-related Kaposi's sarcoma, Am J Ther, 2018; 25:e719-e721 https://doi.org/10.1097/MJT.0000000000000736 PMid:29509553
41. Di Paolo A, Liposomal anticancer therapy: pharmacokinetic and clinical aspects, J Chemother, 2004; 90-93 https://doi.org/10.1179/joc.2004.16.Supplement-1.90 PMid:15688620
42. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S, Albumin-bound formulation of paclitaxel (Abraxane® ABI-007) in the treatment of breast cancer, Int J Nanomed, 2009; 4:99-105 https://doi.org/10.2147/IJN.S3061 PMid:19516888 PMCid:PMC2720743
43. Eloy JO, Claro de Souza M, Petrilli R, Barcellos JPA, Lee RJ, Marchetti JM, Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery, Colloids Surf B Biointerfaces, 2014; 123:345-363 https://doi.org/10.1016/j.colsurfb.2014.09.029 PMid:25280609
44. Ansari L, Shiehzadeh F, Taherzadeh Z, Nikoofal-Sahlabadi S, Momtazi-Borojeni AA, Sahebkar A, Eslami S, The most prevalent side effects of pegylated liposomal doxorubicin monotherapy in women with metastatic breast cancer: a systematic review of clinical trials, Cancer Gene Ther, 2017; 24:189-193 https://doi.org/10.1038/cgt.2017.9 PMid:28409561
45. Fang X, Cao J, Shen A, Advances in anti-breast cancer drugs and the application of nano-drug delivery systems in breast cancer therapy, J Drug Deliv Sci Technol, 2020; 57:101662 https://doi.org/10.1016/j.jddst.2020.101662
46. Shi J, Kantoff PW, Wooster R, Farokhzad OC, Cancer nanomedicine: progress, challenges and opportunities, Nat Rev Cancer, 2017; 17:20-37 https://doi.org/10.1038/nrc.2016.108 PMid:27834398 PMCid:PMC5575742
47. Hare JI, Lammers T, Ashford MB, Puri S, Storm G, Barry ST, Challenges and strategies in anti-cancer nanomedicine development: an industry perspective, Adv Drug Deliv Rev, 2017; 108:25-38 https://doi.org/10.1016/j.addr.2016.04.025 PMid:27137110
48. Bangham AD, A correlation between surface charge and coagulant action of phospholipids, Nature, 1961; 192:1197-1198 https://doi.org/10.1038/1921197a0 PMid:13864660
49. Singh G, Darwin R, Panda KC, Afzal SA, Katiyar S, Dhakar RC, Mani S, Gene expression and hormonal signaling in osteoporosis: from molecular mechanisms to clinical breakthroughs, Journal of Biomaterials Science, Polymer Edition, 2024;1-36 https://doi.org/10.1080/09205063.2024.2445376 https://doi.org/10.1080/09205063.2024.2445376 PMid:39729311
50. Elkhoury K, Koçak P, Kang A, Arab-Tehrany E, Ellis Ward J, Shin SR, Engineering smart targeting nanovesicles and their combination with hydrogels for controlled drug delivery, Pharmaceutics, 2020; 12:849 https://doi.org/10.3390/pharmaceutics12090849 PMid:32906833 PMCid:PMC7559099
51. Velot E, Elkhoury K, Kahn C, Kempf H, Linder M, Arab-Tehrany E, Bianchi A, Efficient TGF-β1 delivery to articular chondrocytes in vitro using agro-based liposomes, Int J Mol Sci, 2022; 23:2864 https://doi.org/10.3390/ijms23052864 PMid:35270005 PMCid:PMC8911360
52. Passeri E, Bun P, Elkhoury K, Linder M, Malaplate C, Yen FT, Arab-Tehrany E, Transfer phenomena of nanoliposomes by live imaging of primary cultures of cortical neurons, Pharmaceutics, 2022; 14:2172 https://doi.org/10.3390/pharmaceutics14102172 PMid:36297607 PMCid:PMC9608836
53. Elkhoury K, Sanchez-Gonzalez L, Lavrador P, Almeida R, Gaspar V, Kahn C, Cleymand F, Arab-Tehrany E, Mano JF, Gelatin methacryloyl (GelMA) nanocomposite hydrogels embedding bioactive Naringin liposomes, Polymers, 2020; 12:2944 https://doi.org/10.3390/polym12122944 PMid:33317207 PMCid:PMC7764353
54. Arab-Tehrany E, Elkhoury K, Francius G, Jierry L, Mano JF, Kahn C, Linder M, Curcumin loaded nanoliposomes localization by nanoscale characterization, Int J Mol Sci, 2020; 21:7276 https://doi.org/10.3390/ijms21197276 PMid:33019782 PMCid:PMC7584047
55. Webster DM, Sundaram P, Byrne ME, Injectable nanomaterials for drug delivery: carriers, targeting moieties, and therapeutics, Eur J Pharm Biopharm, 2013; 84:1-20 https://doi.org/10.1016/j.ejpb.2012.12.009 PMid:23313176
56. Shende P, Ture N, Gaud RS, Trotta F, Lipid- and polymer-based plexes as therapeutic carriers for bioactive molecules, Int J Pharm, 2019; 558:250-260 https://doi.org/10.1016/j.ijpharm.2018.12.085 PMid:30641179
57. Vemuri S, Rhodes CT, Preparation and characterization of liposomes as therapeutic delivery systems: a review, Pharm Acta Helv, 1995; 70:95-111 https://doi.org/10.1016/0031-6865(95)00010-7 PMid:7651973
58. Maurya SD, Prajapati S, Gupta A, Saxena G, Dhakar RC, Formulation Development and Evaluation of Ethosome of Stavudine, Indian J.Pharm. Educ. Res. 2010;44(1)
59. Gregoriadis G, Davis C, Stability of liposomes in vivo and in vitro is promoted by their cholesterol content and the presence of blood cells, Biochem Biophys Res Commun, 1979; 89:1287-1293 https://doi.org/10.1016/0006-291X(79)92148-X PMid:496958
60. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB, Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development, J Pharm Sci, 2008; 97:4696-4740 https://doi.org/10.1002/jps.21358 PMid:18351638
61. Laouini A, Jaafar-Maalej C, Limayem-Blouza I, Sfar S, Charcosset C, Fessi H, Preparation, characterization and applications of liposomes: state of the art, J Colloid Sci Biotechnol, 2012; 1:147-168 https://doi.org/10.1166/jcsb.2012.1020
62. Chaudhry Q, Watkins R, Castle L, Nanotechnologies in food: what, why and how?, RSC Nanosci Nanotechnol, 2017; 1-19 https://doi.org/10.1039/9781782626879-00001 PMCid:PMC5357853
63. Khorasani S, Danaei M, Mozafari MR, Nanoliposome technology for the food and nutraceutical industries, Trends Food Sci Technol, 2018; 79:106-115 https://doi.org/10.1016/j.tifs.2018.07.009
64. Bulbake U, Doppalapudi S, Kommineni N, Khan W, Liposomal formulations in clinical use: an updated review, Pharmaceutics, 2017; 9:12 https://doi.org/10.3390/pharmaceutics9020012 PMid:28346375 PMCid:PMC5489929
65. Saraf S, Jain A, Tiwari A, Verma A, Panda PK, Jain SK, Advances in liposomal drug delivery to cancer: an overview, J Drug Deliv Sci Technol, 2020; 56:101549 https://doi.org/10.1016/j.jddst.2020.101549
66. Large DE, Abdelmessih RG, Fink EA, Auguste DT, Liposome composition in drug delivery design, synthesis, characterization, and clinical application, Adv Drug Deliv Rev, 2021; 176:113851 https://doi.org/10.1016/j.addr.2021.113851 PMid:34224787
67. Elkhoury K, Chen M, Koçak P, Enciso-Martínez E, Bassous NJ, Lee MC, Byambaa B, Rezaei Z, Li Y, Ubina Lopez ME, Gurian M, Sobahi N, Hussain MA, Sanchez-Gonzalez L, Leijten J, Hassan S, Arab-Tehrany E, Ward JE, Shin SR, Hybrid extracellular vesicles-liposome incorporated advanced bioink to deliver microRNA, Biofabrication, 2022; 14:045008 https://doi.org/10.1088/1758-5090/ac8621 PMid:35917808 PMCid:PMC9594995
68. Elkhoury K, Russell CS, Sanchez-Gonzalez L, Mostafavi A, Williams TJ, Kahn C, Peppas NA, Arab-Tehrany E, Tamayol A, Soft-nanoparticle functionalization of natural hydrogels for tissue engineering applications, Adv Healthc Mater, 2019; 8:1900506 https://doi.org/10.1002/adhm.201900506 PMid:31402589 PMCid:PMC6752977
69. Antoniou AI, Giofrè S, Seneci P, Passarella D, Pellegrino S, Stimulus-responsive liposomes for biomedical applications, Drug Discov Today, 2021; 26:1794-1824 https://doi.org/10.1016/j.drudis.2021.05.010 PMid:34058372
70. Srujana S, Anjamma M, Alimuddin, Singh B, Dhakar RC, Natarajan S, Hechhu R. A Comprehensive Study on the Synthesis and Characterization of TiO2 Nanoparticles Using Aloe vera Plant Extract and Their Photocatalytic Activity against MB Dye. Adsorption Science & Technology. 2022;2022 https://doi.org/10.1155/2022/7244006
71. Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL, Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities, J Contr Release, 2018; 277:1-13 https://doi.org/10.1016/j.jconrel.2018.02.040 PMid:29501721
72. Sonju JJ, Dahal A, Singh SS, Jois SD, Peptide-functionalized liposomes as therapeutic and diagnostic tools for cancer treatment, J Contr Release, 2021; 329:624-644 https://doi.org/10.1016/j.jconrel.2020.09.055 PMid:33010333 PMCid:PMC8082750
73. Parajapati S, Maurya S, Das M, Tilak VK, Verma KK, Dhakar RC. Potential Application of Dendrimers in Drug Delivery: A Concise Review and Update. Journal of Drug Delivery and Therapeutics. 2016;6(2):71-88 https://doi.org/10.22270/jddt.v6i2.1195
74. Gabizon A, Peretz T, Sulkes A, Amselem S, Ben-Yosef R, Ben-Baruch N, Catane R, Biran S, Barenholz Y, Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study, Eur J Cancer Clin Oncol, 1989; 25:1795-1803 https://doi.org/10.1016/0277-5379(89)90350-7 PMid:2632261
75. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, Martin F, Huang A, Barenholz Y, Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes, Cancer Res, 1994; 54:987-992
76. Keller AM, Mennel RG, Georgoulias VA, Nabholtz JM, Erazo A, Lluch A, Vogel CL, Kaufmann M, von Minckwitz G, Henderson C, Mellars L, Alland L, Tendler C, Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer, J Clin Oncol, 2004; 22:3893-3901 https://doi.org/10.1200/JCO.2004.08.157 PMid:15459210
77. Batist G, Ramakrishnan G, Rao CS, Chandrasekharan A, Gutheil J, Guthrie T, Shah P, Khojasteh A, Nair MK, Hoelzer K, Tkaczuk K, Park YC, Lee LW, Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer, J Clin Oncol, 2001; 19:1444-1454 https://doi.org/10.1200/JCO.2001.19.5.1444 PMid:11230490
78. Batist G, Barton J, Chaikin P, Swenson C, Welles L, Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy, Expert Opin Pharmacother, 2002; 3:1739-1751 https://doi.org/10.1517/14656566.3.12.1739 PMid:12472371
79. Chan S, Davidson N, Juozaityte E, Erdkamp F, Pluzanska A, Azarnia N, Lee LW, Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer, Ann Oncol, 2004; 15:1527-1532 https://doi.org/10.1093/annonc/mdh393 PMid:15367414
80. Burade V, Bhowmick S, Maiti K, Zalawadia R, Ruan H, Thennati R, Lipodox® (generic doxorubicin hydrochloride liposome injection): in vivo efficacy and bioequivalence versus Caelyx® (doxorubicin hydrochloride liposome injection) in human mammary carcinoma (MX-1) xenograft and syngeneic fibrosarcoma (WEHI 164) mouse models, BMC Cancer, 2017; 17:405 https://doi.org/10.1186/s12885-017-3377-3 PMid:28587612 PMCid:PMC5461687
81. Xu X, Wang L, Xu H, Huang X, Qian Y, Xiang J, Clinical comparison between paclitaxel liposome (Lipusu®) and paclitaxel for treatment of patients with metastatic gastric cancer, Asian Pac J Cancer Prev, 2013; 14:2591-2594 https://doi.org/10.7314/APJCP.2013.14.4.2591 PMid:23725180
82. Wang H, Cheng G, Du Y, Ye L, Chen W, Zhang L, Wang T, Tian J, Fu F, Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation, Mol Med Rep, 2013; 7:947-952 https://doi.org/10.3892/mmr.2013.1264 PMid:23291923 PMCid:PMC3597461
83. Chou H, Lin H, Liu JM, A tale of the two PEGylated liposomal doxorubicins, OncoTargets Ther, 2015; 8:1719-1720 https://doi.org/10.2147/OTT.S79089 PMid:26203262 PMCid:PMC4508070
84. FDA approves generic version of Doxil; expected to help resolve shortage, Oncol Times, 2013; 35:25 https://doi.org/10.1097/01.COT.0000428636.40337.70
85. Barenholz Y, Doxil® - the first FDA-approved nano-drug: lessons learned, J Contr Release, 2012; 160:117-134 https://doi.org/10.1016/j.jconrel.2012.03.020 PMid:22484195
86. Eloy JO, Petrilli R, Trevizan LNF, Chorilli M, Immunoliposomes: a review on functionalization strategies and targets for drug delivery, Colloids Surf B Biointerfaces, 2017; 159:454-467 https://doi.org/10.1016/j.colsurfb.2017.07.085 PMid:28837895
87. Gaspar RS, Florindo HF, Silva LC, Videira MA, Corvo ML, Martins BF, Silva-Lima B, Regulatory Aspects of Oncologicals: Nanosystems Main Challenges, Springer, Cham, 2014; pp. 425-452 https://doi.org/10.1007/978-3-319-08084-0_15
88. Zhu L, Chen L, Progress in research on paclitaxel and tumor immunotherapy, Cell Mol Biol Lett, 2019; 24:1-11 https://doi.org/10.1186/s11658-019-0164-y PMid:31223315 PMCid:PMC6567594
89. Bernabeu E, Cagel M, Lagomarsino E, Moretton M, Chiappetta DA, Paclitaxel: what has been done and the challenges remain ahead, Int J Pharm, 2017; 526:474-495 https://doi.org/10.1016/j.ijpharm.2017.05.016 PMid:28501439
90. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME, Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma, J Clin Oncol, 1996; 14:2353-2364 https://doi.org/10.1200/JCO.1996.14.8.2353 PMid:8708728
91. Bellott R, Auvrignon A, Leblanc T, Péral Y, Gandemer V, Bertrand Y, Méchinaud F, Bellenger P, Vernois J, Leverger G, Baruchel A, Robert J, Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia, Cancer Chemother Pharmacol, 2000; 47:15-21 https://doi.org/10.1007/s002800000206 PMid:11221955
92. O'Byrne KJ, Thomas AL, Sharma RA, DeCatris M, Shields F, Beare S, Steward WP, A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer, Br J Cancer, 2002; 87:15-20 https://doi.org/10.1038/sj.bjc.6600344 PMid:12085249 PMCid:PMC2364277
93. Danhier F, Feron O, Préat V, To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery, J Contr Release, 2010; 148:135-146 https://doi.org/10.1016/j.jconrel.2010.08.027 PMid:20797419
94. Sawant RR, Torchilin VP, Challenges in development of targeted liposomal therapeutics, AAPS J, 2012; 14:303-315 https://doi.org/10.1208/s12248-012-9330-0 PMid:22415612 PMCid:PMC3326155
95. Reineke J, Terminology matters: there is no targeting, but retention, J Contr Release, 2018; 273:180-183 https://doi.org/10.1016/j.jconrel.2018.01.016 PMid:29360476
96. Scherphof GL, Dijkstra J, Spanjer HH, Derksen JT, Roerdink FH, Uptake and intracellular processing of targeted and nontargeted liposomes by rat kupffer cells in vivo and in vitro, Ann NY Acad Sci, 1985; 446:368-384 https://doi.org/10.1111/j.1749-6632.1985.tb18414.x PMid:2409883
97. Longmire M, Choyke PL, Kobayashi H, Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats, Nanomed, 2008; 3:703-717 https://doi.org/10.2217/17435889.3.5.703 PMid:18817471 PMCid:PMC3407669
98. Moghimi SM, Farhangrazi ZS, Nanomedicine and the complement paradigm, Nanomed Nanotechnol Biol Med, 2013; 9:458-460 https://doi.org/10.1016/j.nano.2013.02.011 PMid:23499667
99. Torchilin VP, Targeted pharmaceutical nanocarriers for cancer therapy and imaging, AAPS J, 2007; 9:e128-e147 https://doi.org/10.1208/aapsj0902015 PMid:17614355 PMCid:PMC2751402
100. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM, PEGylation as a strategy for improving nanoparticle-based drug and gene delivery, Adv Drug Deliv Rev, 2016; 99:28-51 https://doi.org/10.1016/j.addr.2015.09.012 PMid:26456916 PMCid:PMC4798869
101. Charrois GJR, Allen TM, Multiple injections of pegylated liposomal doxorubicin: pharmacokinetics and therapeutic activity, J Pharmacol Exp Ther, 2003; 306:1058-1067 https://doi.org/10.1124/jpet.103.053413 PMid:12808004
102. Gu W, Meng F, Haag R, Zhong Z, Actively targeted nanomedicines for precision cancer therapy: concept, construction, challenges and clinical translation, J Contr Release, 2021; 329:676-695 https://doi.org/10.1016/j.jconrel.2020.10.003 PMid:33022328
103. Almeida B, Nag OK, Rogers KE, Delehanty JB, Recent progress in bioconjugation strategies for liposome-mediated drug delivery, Mol Basel Switz, 2020; 25:5672 https://doi.org/10.3390/molecules25235672 PMid:33271886 PMCid:PMC7730700
104. de Lima PHC, Butera AP, Cabeça LF, Ribeiro-Viana RM, Liposome surface modification by phospholipid chemical reactions, Chem Phys Lipids, 2021; 237:105084 https://doi.org/10.1016/j.chemphyslip.2021.105084 PMid:33891960
105. Marqués-Gallego P, de Kroon AIPM, Ligation strategies for targeting liposomal nanocarriers, BioMed Res Int, 2014; 2014:e129458 https://doi.org/10.1155/2014/129458 PMid:25126543 PMCid:PMC4122157
106. Taiariol L, Chaix C, Farre C, Moreau E, Click and bioorthogonal chemistry: the future of active targeting of nanoparticles for nanomedicines?, Chem Rev, 2022; 122:340-384 https://doi.org/10.1021/acs.chemrev.1c00484 PMid:34705429
107. Riaz M, Riaz M, Zhang X, Lin C, Wong K, Chen X, Zhang G, Lu A, Yang Z, Surface functionalization and targeting strategies of liposomes in solid tumor therapy: a review, Int J Mol Sci, 2018; 19:195 https://doi.org/10.3390/ijms19010195 PMid:29315231 PMCid:PMC5796144
108. Crivianu-Gaita V, Thompson M, Aptamers, antibody scFv, and antibody Fab' fragments: an overview and comparison of three of the most versatile biosensor biorecognition elements, Biosens Bioelectron, 2016; 85:32-45 https://doi.org/10.1016/j.bios.2016.04.091 PMid:27155114
109. Forssen E, Willis M, Ligand-targeted liposomes, Adv Drug Deliv Rev, 1998; 29:249-271 https://doi.org/10.1016/S0169-409X(97)00083-5 PMid:10837594
110. Ruoslahti E, Peptides as targeting elements and tissue penetration devices for nanoparticles, Adv Mater, 2012; 24:3747-3756 https://doi.org/10.1002/adma.201200454 PMid:22550056 PMCid:PMC3947925
111. Xu Y, Phillips JA, Yan J, Li Q, Fan ZH, Tan W, Aptamer-based microfluidic device for enrichment, sorting, and detection of multiple cancer cells, Anal Chem, 2009; 81:7436-7442 https://doi.org/10.1021/ac9012072 PMid:19715365 PMCid:PMC3164879
112. Dickey DD, Giangrande PH, Oligonucleotide aptamers: a next-generation technology for the capture and detection of circulating tumor cells, Methods, 2016; 97:94-103 https://doi.org/10.1016/j.ymeth.2015.11.020 PMid:26631715 PMCid:PMC4792782
113. Zhou Z, Liu M, Jiang J, The potential of aptamers for cancer research, Anal Biochem, 2018; 549:91-95 https://doi.org/10.1016/j.ab.2018.03.008 PMid:29548926
114. Guo P, You J-O, Yang J, Jia D, Moses MA, Auguste DT, Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade, Mol Pharm, 2014; 11:755-765 https://doi.org/10.1021/mp4004699 PMid:24467226 PMCid:PMC3993942
115. Liu D, Guo P, McCarthy C, Wang B, Tao Y, Auguste DT, Peptide density targets and impedes triple negative breast cancer metastasis, Nat Commun, 2018; 9:1-11 https://doi.org/10.1038/s41467-018-05035-5 PMid:29973594 PMCid:PMC6031661
116. Lu G, Qiu Y, Su X, Targeting CXCL12-CXCR4 signaling enhances immune checkpoint blockade therapy against triple negative breast cancer, Eur J Pharmaceut Sci, 2021; 157:105606 https://doi.org/10.1016/j.ejps.2020.105606 PMid:33131745
117. Zhang K, Fang X, You Q, Lin Y, Ma L, Xu S, Ge Y, Xu H, Yang Y, Wang C, Novel peptide-directed liposomes for targeted combination therapy of breast tumors, Mater Adv, 2020; 1:3483-3495 https://doi.org/10.1039/D0MA00536C
118. Lukyanov AN, Elbayoumi TA, Chakilam AR, Torchilin VP, Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anticancer antibody, J Contr Release, 2004; 100:135-144 https://doi.org/10.1016/j.jconrel.2004.08.007 PMid:15491817
119. Elbayoumi T, Torchilin V, Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines, Eur J Pharmaceut Sci, 2007; 32:159-168 https://doi.org/10.1016/j.ejps.2007.05.113 PMid:17707615 PMCid:PMC2151083
120. Elbayoumi T, Torchilin VP, Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody, Clin Cancer Res, 2009; 15:1973-1980 https://doi.org/10.1158/1078-0432.CCR-08-2392 PMid:19276264 PMCid:PMC2762655
121. Narayanaswamy R, Torchilin VP, Targeted delivery of combination therapeutics using monoclonal antibody 2C5-modified immunoliposomes for cancer therapy, Pharm Res, 2021; 38:429-450 https://doi.org/10.1007/s11095-021-02986-1 PMid:33655395
122. Kamoun WS, Kirpotin DB, Huang ZR, Tipparaju SK, Noble CO, Hayes ME, Luus L, Koshkaryev A, Kim J, Olivier K, Kornaga T, Oyama S, Askoxylakis V, Pien C, Kuesters G, Dumont N, Lugovskoy AA, Schihl SA, Wilton JH, Geddie ML, Suchy J, Grabow S, Kohli N, Reynolds CP, Blaydes R, Zhou Y, Sawyer AJ, Marks JD, Drummond DC, Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models, Nat Biomed Eng, 2019; 3:264-280 https://doi.org/10.1038/s41551-019-0385-4 PMid:30952988
123. Kamoun WS, Dugast A-S, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ, Synergy between EphA2-ILs-DTXp, a novel EphA2-targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models, Mol Cancer Therapeut, 2020; 19:270-281 https://doi.org/10.1158/1535-7163.MCT-19-0414 PMid:31597714
124. Guo Z, He B, Yuan L, Dai W, Zhang H, Wang X, Wang J, Zhang X, Zhang Q, Dual targeting for metastatic breast cancer and tumor neovasculature by EphA2-mediated nanocarriers, Int J Pharm, 2015; 493:380-389 https://doi.org/10.1016/j.ijpharm.2015.05.051 PMid:26004003
125. Barbosa MV, Monteiro LOF, Carneiro G, Malagutti AR, Vilela JMC, Andrade MS, Oliveira MC, Carvalho-Junior AD, Leite EA, Experimental design of a liposomal lipid system: a potential strategy for paclitaxel-based breast cancer treatment, Colloids Surf B Biointerfaces, 2015; 136:553-561 https://doi.org/10.1016/j.colsurfb.2015.09.055 PMid:26454545
126. Monteiro LOF, Fernandes RS, Oda CMR, Lopes SC, Townsend DM, Cardoso VN, Oliveira MC, Leite EA, Rubello D, Barros ALB, Paclitaxel-loaded folate-coated long circulating and pH-sensitive liposomes as a potential drug delivery system: a biodistribution study, Biomed Pharmacother, 2018; 97:489-495 https://doi.org/10.1016/j.biopha.2017.10.135 PMid:29091899 PMCid:PMC6361139
127. de Oliveira Silva J, Fernandes RS, Ramos Oda CM, Ferreira TH, Machado Botelho AF, Martins Melo M, de Miranda MC, Assis Gomes D, Dantas Cassali G, Townsend DM, Rubello D, Oliveira MC, Barros ALB, Folate-coated, long-circulating and pH-sensitive liposomes enhance doxorubicin antitumor effect in a breast cancer animal model, Biomed Pharmacother, 2019; 118:109323 https://doi.org/10.1016/j.biopha.2019.109323 PMid:31400669 PMCid:PMC7104811
128. Chen Y, Cheng Y, Zhao P, Zhang S, Li M, He C, Zhang X, Yang T, Yan R, Ye P, Ma X, Xiang G, Co-delivery of doxorubicin and imatinib by pH sensitive cleavable PEGylated nanoliposomes with folate-mediated targeting to overcome multidrug resistance, Int J Pharm, 2018; 542:266-279 https://doi.org/10.1016/j.ijpharm.2018.03.024 PMid:29551747
129. Soe ZC, Thapa RK, Ou W, Gautam M, Nguyen HT, Jin SG, Ku SK, Oh KT, Choi HG, Yong CS, Kim JO, Folate receptor-mediated celastrol and irinotecan combination delivery using liposomes for effective chemotherapy, Colloids Surf B Biointerfaces, 2018; 170:718-728 https://doi.org/10.1016/j.colsurfb.2018.07.013 PMid:30005409
130. Du Nguyen V, Min HK, Kim CS, Han J, Park JO, Choi E, Folate receptor-targeted liposomal nanocomplex for effective synergistic photothermal-chemotherapy of breast cancer in vivo, Colloids Surf B Biointerfaces, 2019; 173:539-548 https://doi.org/10.1016/j.colsurfb.2018.10.013 PMid:30343218
131. Sneider A, Jadia R, Piel B, Van Dyke D, Tsiros C, Rai P, Engineering remotely triggered liposomes to target triple negative breast cancer, Oncomedicine, 2017; 2:1-13 https://doi.org/10.7150/oncm.17406 PMid:28174679 PMCid:PMC5292187
132. Gazzano E, Rolando B, Chegaev K, Salaroglio C, Kopecka J, Pedrini I, Saponara S, Sorge M, Buondonno I, Stella B, Marengo A, Valoti M, Brancaccio M, Fruttero R, Gasco A, Arpicco S, Riganti C, Folate-targeted liposomal nitrooxy-doxorubicin: an effective tool against P-glycoprotein-positive and folate receptor-positive tumors, J Contr Release, 2018; 270:37-52 https://doi.org/10.1016/j.jconrel.2017.11.042 PMid:29191785
133. Deng C, Zhang Q, Jia M, Zhao J, Sun X, Gong T, Zhang Z, Tumors and their microenvironment dual-targeting chemotherapy with local immune adjuvant therapy for effective antitumor immunity against breast cancer, Adv Sci, 2019; 6:1801868 https://doi.org/10.1002/advs.201801868 PMid:30937266 PMCid:PMC6425447
134. Guo P, Yang J, Jia D, Moses MA, Auguste DT, ICAM-1-targeted, Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic agents for triple negative breast cancer, Theranostics, 2016; 6:1-15 https://doi.org/10.7150/thno.12167 PMid:26722369 PMCid:PMC4679350
135. Orthmann A, Zeisig R, Süss R, Lorenz D, Lemm M, Fichtner I, Treatment of experimental brain metastasis with MTO-liposomes: impact of fluidity and LRP-targeting on the therapeutic result, Pharm Res, 2012; 29:1949-1959 https://doi.org/10.1007/s11095-012-0723-7 PMid:22399388
136. Orthmann A, Peiker L, Fichtner I, Hoffmann A, Hilger R, Zeisig R, Improved treatment of MT-3 breast cancer and brain metastases in a mouse xenograft by LRP-targeted oxaliplatin liposomes, J Biomed Nanotechnol, 2016; 12:56-68 https://doi.org/10.1166/jbn.2016.2143 PMid:27301172
137. Moura V, Lacerda M, Figueiredo P, Corvo M, Cruz M, Soares R, de Lima M, Simoes J, Moreira J, Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer, Breast Cancer Res Treat, 2012; 133:61-73 https://doi.org/10.1007/s10549-011-1688-7 PMid:21805188
138. Fonseca NA, Rodrigues AS, Rodrigues-Santos P, Alves V, Gregorio AC, Valério-Fernandes Á, Gomes-da-Silva LC, Rosa MS, Moura V, Ramalho-Santos J, Simoes J, Moreira JN, Nucleolin overexpression in breast cancer cell sub-populations with different stem-like phenotype enables targeted intracellular delivery of synergistic drug combination, Biomaterials, 2015; 69:76-88 https://doi.org/10.1016/j.biomaterials.2015.08.007 PMid:26283155
139. Xing H, Tang L, Yang X, Hwang K, Wang W, Yin Q, Wong N, Dobrucki L, Yasui N, Katzenellenbogen J, Helferich W, Cheng J, Lu Y, Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo, J Mater Chem B, 2013; 1:5288-5297 https://doi.org/10.1039/c3tb20412j PMid:24159374 PMCid:PMC3800741
140. Liao ZX, Chuang EY, Lin CC, Ho YC, Lin KJ, Cheng PY, Chen KJ, Wei HJ, Sung HW, An AS1411 aptamer-conjugated liposomal system containing a bubble-generating agent for tumor-specific chemotherapy that overcomes multidrug resistance, J Contr Release, 2015; 208:42-51 https://doi.org/10.1016/j.jconrel.2015.01.032 PMid:25637705
141. Li X, Wu X, Yang H, Li L, Ye Z, Rao Y, A nuclear targeted Dox-aptamer loaded liposome delivery platform for the circumvention of drug resistance in breast cancer, Biomed Pharmacother, 2019; 117:109072 https://doi.org/10.1016/j.biopha.2019.109072 PMid:31202169
142. Yu S, Bi X, Yang L, Wu S, Yu Y, Jiang B, Zhang A, Lan K, Duan S, Co-delivery of paclitaxel and PLK1-targeted siRNA using aptamer-functionalized cationic liposome for synergistic anti-breast cancer effects in vivo, J Biomed Nanotechnol, 2019; 15:1135-1148 https://doi.org/10.1166/jbn.2019.2751 PMid:31072423
143. Abnous K, Danesh NM, Ramezani M, Alibolandi M, Bahreyni A, Lavaee P, Moosavian SA, Taghdisi SM, A smart ATP-responsive chemotherapy drug-free delivery system using a DNA nanostructure for synergistic treatment of breast cancer in vitro and in vivo, J Drug Target, 2020; 28:852-859 https://doi.org/10.1080/1061186X.2020.1712407 PMid:31916879
144. Shi J, Sun M, Li X, Zhao Y, Ju R, Mu L, Yan Y, Li X, Zeng F, Lu W, A combination of targeted sunitinib liposomes and targeted vinorelbine liposomes for treating invasive breast cancer, J Biomed Nanotechnol, 2015; 11:1568-1582 https://doi.org/10.1166/jbn.2015.2075 PMid:26485927
145. Han S, Baek J, Kim M, Hwang S, Cho C, Surface modification of paclitaxel-loaded liposomes using d-α-tocopheryl polyethylene glycol 1000 succinate: enhanced cellular uptake and cytotoxicity in multidrug resistant breast cancer cells, Chem Phys Lipids, 2018; 213:39-47 https://doi.org/10.1016/j.chemphyslip.2018.03.005 PMid:29550143
146. Li N, Fu T, Fei W, Han T, Gu X, Hou Y, Liu Y, Yang J, Vitamin E D-α-tocopheryl polyethylene glycol 1000 succinate-conjugated liposomal docetaxel reverses multidrug resistance in breast cancer cells, J Pharm Pharmacol, 2019; 71:1243-1254 https://doi.org/10.1111/jphp.13126 PMid:31215039
147. Bharti R, Dey G, Banerjee I, Dey KK, Parida S, Kumar BNP, Das CK, Pal I, Mukherjee M, Misra M, Pradhan AK, Emdad L, Das SK, Fisher PB, Mandal M, Somatostatin receptor targeted liposomes with Diacerein inhibit IL-6 for breast cancer therapy, Cancer Lett, 2017; 388:292-302 https://doi.org/10.1016/j.canlet.2016.12.021 PMid:28025102
148. Ju RJ, Cheng L, Peng XM, Wang T, Li CQ, Song XL, Liu S, Chao JP, Li XT, Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer, Artif Cell Nanomed Biotechnol, 2018; 46:616-628 https://doi.org/10.1080/21691401.2018.1433187 PMid:29381101
149. Gote V, Pal D, Octreotide-targeted Lcn2 siRNA PEGylated liposomes as a treatment for metastatic breast cancer, Bioengineering, 2021; 8:44 https://doi.org/10.3390/bioengineering8040044 PMid:33916786 PMCid:PMC8067132
150. Mukherjee A, Prasad TK, Rao NM, Banerjee R, Haloperidol-associated stealth liposomes: a potent carrier for delivering genes to human breast cancer cells, J Biol Chem, 2005; 280:15619-15627 https://doi.org/10.1074/jbc.M409723200 PMid:15695518
151. Zhang Y, Huang Y, Zhang P, Gao X, Gibbs RB, Li S, Incorporation of a selective sigma-2 receptor ligand enhances uptake of liposomes by multiple cancer cells, Int J Nanomed, 2012; 7:4473 https://doi.org/10.2147/IJN.S31981 PMid:22927761 PMCid:PMC3422102
152. Gandhi R, Khatri N, Baradia D, Vhora I, Misra A, Surface-modified Epirubicin HCl liposomes and its in vitro assessment in breast cancer cell-line: MCF-7, Drug Deliv, 2015; 23:1152-1162 https://doi.org/10.3109/10717544.2014.999960 PMid:25586675
153. Fu J, Li W, Xin X, Chen D, Hu H, Transferrin-modified nanoliposome co-delivery strategies for enhancing the cancer therapy, J Pharm Sci, 2020; 109:2426-2436 https://doi.org/10.1016/j.xphs.2019.11.013 PMid:31760084
154. Belfiore L, Saunders D, Ranson M, Vine K, N-Alkylisatin-loaded liposomes target the urokinase plasminogen activator system in breast cancer, Pharmaceutics, 2020; 12:641 https://doi.org/10.3390/pharmaceutics12070641 PMid:32645963 PMCid:PMC7408009
155. Cochran BJ, Croucher DR, Lobov S, Saunders DN, Ranson M, Dependence on endocytic receptor binding via a minimal binding motif underlies the differential prognostic profiles of SerpinE1 and SerpinB2 in cancer, J Biol Chem, 2011; 286:24467-24475 https://doi.org/10.1074/jbc.M111.225706 PMid:21606492 PMCid:PMC3129226
156. Stutchbury TK, Al-ejeh F, Stillfried GE, Croucher DR, Andrews J, Irving D, Links M, Ranson M, Preclinical evaluation of 213Bi-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma, Mol Cancer Therapeut, 2007; 6:203-212 https://doi.org/10.1158/1535-7163.MCT-06-0264 PMid:17237280
157. Lu R, Zhou L, Yue Q, Liu Q, Cai X, Xiao W, Hai L, Guo L, Wu Y, Liposomes modified with double-branched biotin: a novel and effective way to promote breast cancer targeting, Bioorg Med Chem, 2019; 27:3115-3127 https://doi.org/10.1016/j.bmc.2019.05.039 PMid:31155297
158. Tang B, Peng Y, Yue Q, Pu Y, Li R, Zhao Y, Hai L, Guo L, Wu Y, Design, preparation and evaluation of different branched biotin modified liposomes for targeting breast cancer, Eur J Med Chem, 2020; 193:112204 https://doi.org/10.1016/j.ejmech.2020.112204 PMid:32172035
159. Huang M, Pu Y, Peng Y, Fu Q, Guo L, Wu Y, Zheng Y, Biotin and glucose dual-targeting, ligand-modified liposomes promote breast tumor-specific drug delivery, Bioorg Med Chem Lett, 2020; 30:127151 https://doi.org/10.1016/j.bmcl.2020.127151 PMid:32317211
160. Lv Y, Xu C, Zhao X, Lin C, Yang X, Xin X, Zhang L, Qin C, Han X, Yang L, He W, Yin L, Nanoplatform assembled from a CD44-targeted prodrug and smart liposomes for dual targeting of tumor microenvironment and cancer cells, ACS Nano, 2018; 12:1519-1536 https://doi.org/10.1021/acsnano.7b08051 PMid:29350904
161. Han NK, Shin DH, Kim JS, Weon KY, Jang CY, Kim JS, Hyaluronan-conjugated liposomes encapsulating gemcitabine for breast cancer stem cells, Int J Nanomed, 2016; 11:1413-1426 https://doi.org/10.2147/IJN.S95850 PMid:27103799 PMCid:PMC4827594
162. Jiang T, Mo R, Bellotti A, Zhou J, Gu Z, Gel-liposome-mediated co-delivery of anticancer membrane-associated proteins and small-molecule drugs for enhanced therapeutic efficacy, Adv Funct Mater, 2014; 24:2295-2304 https://doi.org/10.1002/adfm.201303222
163. Ding Y, Yang R, Yu W, Hu C, Zhang Z, Liu D, An Y, Wang X, He C, Liu P, Tang Q, Chen D, Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer, J Nanobiotechnol, 2021; 19:1-17 https://doi.org/10.1186/s12951-021-00891-8 PMid:34011362 PMCid:PMC8136194
164. Yang R, Lu M, Ming L, Chen Y, Cheng K, Zhou J, Jiang S, Lin Z, Chen D, 89Zr-labeled multifunctional liposomes conjugate chitosan for PET-trackable triple-negative breast cancer stem cell targeted therapy, Int J Nanomed, 2020; 15:9061-9078 https://doi.org/10.2147/IJN.S262786 PMid:33239874 PMCid:PMC7680801
165. He Y, Zhang L, Song C, Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes, Int J Nanomed, 2010; 5:697-705 https://doi.org/10.2147/IJN.S12129 PMid:20957221 PMCid:PMC2948949
166. He Y, Zhang L, Zhu D, Song C, Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy, Int J Nanomed, 2014; 9:4055-4066 https://doi.org/10.2147/IJN.S61880 Mid:25187709 PMCid:PMC4149452
167. Paliwal S, Paliwal R, Pal H, Saxena A, Sharma P, Gupta P, Agrawal G, Vyas S, Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy, Mol Pharm, 2012; 9:176-186 https://doi.org/10.1021/mp200439z PMid:22091702
168. Salkho NM, Paul V, Kawak P, Vitor RF, Martins AM, Al Sayah M, Husseini GA, Ultrasonically controlled estrone-modified liposomes for estrogen-positive breast cancer therapy, Artif Cell Nanomed Biotechnol, 2018; 46:462-472 https://doi.org/10.1080/21691401.2018.1459634 PMid:29644867
169. Han B, Yang Y, Chen J, Tang H, Sun Y, Zhang Z, Wang Z, Li Y, Li Y, Luan X, Li Q, Ren Z, Zhou X, Cong D, Liu Z, Meng Q, Sun F, Pei J, Preparation, characterization, and pharmacokinetic study of a novel long-acting targeted paclitaxel liposome with antitumor activity, Int J Nanomed, 2020; 15:553-571 https://doi.org/10.2147/IJN.S228715 PMid:32158208 PMCid:PMC6986409
170. Qin C, He B, Dai W, Zhang H, Wang X, Wang J, Zhang X, Wang G, Yin L, Zhang Q, Inhibition of metastatic tumor growth and metastasis via targeting metastatic breast cancer by chlorotoxin-modified liposomes, Mol Pharm, 2014; 11:3233-3241 https://doi.org/10.1021/mp400691z PMid:24559485
171. strem RG, Parhamifar L, Pourhassan H, Clergeaud G, Nielsen OL, Kjær A, Hansen AE, Andresen TL, Secretory phospholipase A2 responsive liposomes exhibit a potent anti-neoplastic effect in vitro, but induce unforeseen severe toxicity in vivo, J Contr Release, 2017; 262:212-221 https://doi.org/10.1016/j.jconrel.2017.07.031 PMid:28754610
172. Oshiro-Júnior J, Rodero C, Hanck-Silva G, Sato M, Alves R, Eloy J, Chorilli M, Stimuli-responsive drug delivery nanocarriers in the treatment of breast cancer, Curr Med Chem, 2020; 27:2494-2513 https://doi.org/10.2174/0929867325666181009120610 PMid:30306849
173. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A, Involvement of chemokine receptors in breast cancer metastasis, Nature, 2001; 410:50-56 https://doi.org/10.1038/35065016 PMid:11242036
174. Zlotnik A, Chemokines and cancer, Int J Cancer, 2006; 119:2026-2029 https://doi.org/10.1002/ijc.22024 PMid:16671092
175. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA, A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1), J Exp Med, 1996; 184:1101-1109 https://doi.org/10.1084/jem.184.3.1101 PMid:9064327 PMCid:PMC2192798
176. Mukherjee D, Zhao J, The role of chemokine receptor CXCR4 in breast cancer metastasis, Am J Cancer Res, 2013; 3:46-57
177. Wang Y, Xie Y, Oupický D, Potential of CXCR4/CXCL12 chemokine axis in cancer drug delivery, Curr Pharmacol Rep, 2016; 2:1-10 https://doi.org/10.1007/s40495-015-0044-8 PMid:27088072 PMCid:PMC4827436
178. Robertson JM, James JA, Preclinical systemic lupus erythematosus, Rheum Dis Clin, 2014; 40:621-635 https://doi.org/10.1016/j.rdc.2014.07.004 PMid:25437281 PMCid:PMC4301850
179. Vlagea A, Falagan S, Gutiérrez-Gutiérrez G, Moreno-Rubio J, Merino M, Zambrana F, Casado E, Sereno M, Antinuclear antibodies and cancer: a literature review, Crit Rev Oncol Hematol, 2018; 127:42-49 https://doi.org/10.1016/j.critrevonc.2018.05.002 PMid:29891110
180. Nisihara R, Machoski M, Neppel A, Maestri C, Messias-Reason I, Skare T, Antinuclear antibodies in patients with breast cancer, Clin Exp Immunol, 2018; 193:178-182 https://doi.org/10.1111/cei.13136 PMid:29645079 PMCid:PMC6046476
181. Wilson K, Shiuan E, Brantley-Sieders DM, Oncogenic functions and therapeutic targeting of EphA2 in cancer, Oncogene, 2021; 40:2483-2498 https://doi.org/10.1038/s41388-021-01714-8 PMid:33686241 PMCid:PMC8035212
182. Xiao T, Xiao Y, Wang W, Tang YY, Xiao Z, Su M, Targeting EphA2 in cancer, J Hematol Oncol, 2020; 13:1-17 https://doi.org/10.1186/s13045-020-00944-9 PMid:32811512 PMCid:PMC7433191
183. Zhao P, Jiang D, Huang Y, Chen C, EphA2: a promising therapeutic target in breast cancer, J Genet Genomics, 2021; 48:261-267 https://doi.org/10.1016/j.jgg.2021.02.011 PMid:33962882
184. Ernstoff MS, Ma WW, Tsai FYC, Munster PN, Zhang T, Kamoun W, Pipas JM, Chen S, Santillana S, Askoxylakis V, A phase 1 study evaluating the safety, pharmacology and preliminary activity of MM-310 in patients with solid tumors, J Clin Oncol, 2018; 36:TPS2604 https://doi.org/10.1200/JCO.2018.36.15_suppl.TPS2604
185. Kamoun WS, Dugast AS, Suchy JJ, Grabow S, Fulton RB, Sampson JF, Luus L, Santiago M, Koshkaryev A, Sun G, Askoxylakis V, Tam E, Huang ZR, Drummond DC, Sawyer AJ, Synergy between EphA2-ILs-DTXp, a novel EphA2-targeted nanoliposomal taxane, and PD-1 inhibitors in preclinical tumor models, Mol Cancer Therapeut, 2020; 19:270-281 https://doi.org/10.1158/1535-7163.MCT-19-0414 PMid:31597714
186. Kumar P, Huo P, Liu B, Formulation strategies for folate-targeted liposomes and their biomedical applications, Pharmaceutics, 2019; 11:381 https://doi.org/10.3390/pharmaceutics11080381 PMid:31382369 PMCid:PMC6722551
187. Xu L, Bai Q, Zhang X, Yang H, Folate-mediated chemotherapy and diagnostics: an updated review and outlook, J Contr Release, 2017; 252:73-82 https://doi.org/10.1016/j.jconrel.2017.02.023 PMid:28235591 PMCid:PMC5479736
188. Tagde P, Kulkarni GT, Mishra DK, Kesharwani P, Recent advances in folic acid engineered nanocarriers for treatment of breast cancer, J Drug Deliv Sci Technol, 2020; 56:101613 https://doi.org/10.1016/j.jddst.2020.101613 189. Zempleni J, Wijeratne S, Hassan Y, Biotin, BioFactors, 2009; 35:36-46 https://doi.org/10.1002/biof.8 PMid:19319844 PMCid:PMC4757853
190. Vadlapudi A, Vadlapatla R, Mitra A, Sodium dependent multivitamin transporter (SMVT): a potential target for drug delivery, Curr Drug Targets, 2012; 13:994-1003 https://doi.org/10.2174/138945012800675650 PMid:22420308 PMCid:PMC4406285
191. Vadlapudi AD, Vadlapatla RK, Pal D, Mitra AK, Biotin uptake by T47D breast cancer cells: functional and molecular evidence of sodium-dependent multivitamin transporter (SMVT), Int J Pharm, 2013; 441:535-543 https://doi.org/10.1016/j.ijpharm.2012.10.047 PMid:23142496
192. Ren WX, Han J, Uhm S, Jang YJ, Kang C, Kim JH, Kim JS, Recent development of biotin conjugation in biological imaging, sensing, and target delivery, Chem Commun, 2015; 51:10403-10418 https://doi.org/10.1039/C5CC03075G PMid:26021457
193. Zheng Z, Shao N, Weng H, Li W, Zhang J, Zhang L, Yang L, Ye S, Correlation between epidermal growth factor receptor and tumor stem cell markers CD44/CD24 and their relationship with prognosis in breast invasive ductal carcinoma, Med Oncol, 2015; 32:1-11 https://doi.org/10.1007/s12032-014-0275-2 PMid:25429827 PMCid:PMC4246130
194. Jin J, Krishnamachary B, Mironchik Y, Kobayashi H, Bhujwalla ZM, Phototheranostics of CD44-positive cell populations in triple negative breast cancer, Sci Rep, 2016; 6:1-12 https://doi.org/10.1038/srep27871 PMid:27302409 PMCid:PMC4908597
195. Yang C, He Y, Zhang H, Liu Y, Wang W, Du Y, Gao F, Selective killing of breast cancer cells expressing activated CD44 using CD44 ligand-coated nanoparticles in vitro and in vivo, Oncotarget, 2015; 6:15283-15296 https://doi.org/10.18632/oncotarget.3681 PMid:25909172 PMCid:PMC4558151
196. Gupta R, Lall R, Srivastava A, Sinha A, Hyaluronic acid: molecular mechanisms and therapeutic trajectory, Front Vet Sci, 2019; 6:192 https://doi.org/10.3389/fvets.2019.00192 PMid:31294035 PMCid:PMC6603175
197. Lee HJ, Seo AN, Kim EJ, Jang MH, Kim YJ, Kim JH, Kim SW, Ryu HS, Park IA, Im SA, Gong G, Jung KH, Kim HJ, Park SY, Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer, Br J Cancer, 2015; 112:103-111 https://doi.org/10.1038/bjc.2014.556 PMid:25349977 PMCid:PMC4453607
198. Luiz MT, Dutra JAP, Tofani LB, de Araújo JTC, Di Filippo LD, Marchetti JM, Chorilli M, Targeted liposomes: a nonviral gene delivery system for cancer therapy, Pharmaceutics, 2022; 14:821 https://doi.org/10.3390/pharmaceutics14040821 PMid:35456655 PMCid:PMC9030342
199. Bou-Assaly W, Mukherji S, Cetuximab (Erbitux), Am J Neuroradiol, 2010; 31:626-627 https://doi.org/10.3174/ajnr.A2054 PMid:20167650 PMCid:PMC7964212
200. Flanagan CA, Manilall A, Gonadotropin-releasing hormone (GnRH) receptor structure and GnRH binding, Front Endocrinol, 2017; 8:274 https://doi.org/10.3389/fendo.2017.00274 PMid:29123501 PMCid:PMC5662886
201. Schally AV, Szepeshazi K, Nagy A, Comaru-Schally AM, Halmos G, New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs, Cell Mol Life Sci, 2004; 61:1042-1068 https://doi.org/10.1007/s00018-004-3434-3 PMid:15112052 PMCid:PMC11138622
202. Wu Y, Zhang Z, Cenciarini ME, Proietti CJ, Amasino M, Hong T, Yang M, Liao Y, Chiang HC, Kaklamani VG, Jeselsohn R, Vadlamudi RK, Huang THM, Li R, De Angelis C, Fu X, Elizalde PV, Schiff R, Brown M, Xu K, Tamoxifen resistance in breast cancer is regulated by the EZH2-ERα-GREB1 transcriptional axis, Cancer Res, 2018; 78:671-684 https://doi.org/10.1158/0008-5472.CAN-17-1327 PMid:29212856 PMCid:PMC5967248
203. Jallow F, O'Leary KA, Rugowski DE, Guerrero JF, Ponik SM, Schuler LA, Dynamic interactions between the extracellular matrix and estrogen activity in progression of ER+ breast cancer, Oncogene, 2019; 38:6913-6925 https://doi.org/10.1038/s41388-019-0941-0 PMid:31406251 PMCid:PMC6814534
204. Liu Y, Ma H, Yao J, ERα, a key target for cancer therapy: a review, OncoTargets Ther, 2020; 13:2183-2191 https://doi.org/10.2147/OTT.S236532 PMid:32210584 PMCid:PMC7073439
205. Omoto Y, Iwase H, Clinical significance of estrogen receptor β in breast and prostate cancer from biological aspects, Cancer Sci, 2015; 106:337-343 https://doi.org/10.1111/cas.12613 PMid:25611678 PMCid:PMC4409875
206. Arnal JF, Lenfant F, Metivier R, Flouriot G, Henrion D, Adlanmerini M, Fontaine C, Gourdy P, Chambon P, Katzenellenbogen B, Katzenellenbogen J, Membrane and nuclear estrogen receptor alpha actions: from tissue specificity to medical implications, Physiol Rev, 2017; 97:1045-1087 https://doi.org/10.1152/physrev.00024.2016 PMid:28539435
207. Spooner D, Litton A, Chlebowski RT, Caffier H, Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials, Lancet, 2005; 365:1687-1717 https://doi.org/10.1016/S0140-6736(05)66544-0 PMid:15894097
208. Yan C, Boyd D, Regulation of matrix metalloproteinase gene expression, J Cell Physiol, 2007; 211:19-26 https://doi.org/10.1002/jcp.20948 PMid:17167774
209. Cathcart J, Pulkoski-Gross A, Cao J, Targeting matrix metalloproteinases in cancer: bringing new life to old ideas, Genes Dis, 2015; 2:26-34 https://doi.org/10.1016/j.gendis.2014.12.002 PMid:26097889 PMCid:PMC4474140
210. Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A, Matrix metalloproteinases: a challenging paradigm of cancer management, Semin Cancer Biol, 2019; 56:100-115 https://doi.org/10.1016/j.semcancer.2017.11.008 PMid:29155240
211. Medina OP, Haikola M, Tahtinen M, Simpura I, Kaukinen S, Valtanen H, Zhu Y, Kuosmanen S, Cao W, Reunanen J, Nurminen T, Saris PEJ, Smith-Jones P, Bradbury M, Larson S, Kairemo K, Liposomal tumor targeting in drug delivery utilizing MMP-2- and MMP-9-binding ligands, J Drug Deliv, 2011; 2011:1-9 https://doi.org/10.1155/2011/160515 PMid:21490745 PMCid:PMC3066593
212. Isaacson KJ, Jensen MM, Subrahmanyam NB, Ghandehari H, Matrix metalloproteinases as targets for controlled delivery in cancer: an analysis of upregulation and expression, J Contr Release, 2017; 259:62-72 https://doi.org/10.1016/j.jconrel.2017.01.034 PMid:28153760 PMCid:PMC5537048
213. Quach ND, Arnold RD, Cummings BS, Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease, Biochem Pharmacol, 2014; 90:338-348 https://doi.org/10.1016/j.bcp.2014.05.022 PMid:24907600 PMCid:PMC4104246
214. Yamashita S, Yamashita J, Ogawa M, Overexpression of group II phospholipase A2 in human breast cancer tissues is closely associated with their malignant potency, Br J Cancer, 1994; 69:1166-1170 https://doi.org/10.1038/bjc.1994.229 PMid:8198986 PMCid:PMC1969450
215. Dennis E, Cao J, Hsu Y, Magrioti V, Kokotos G, Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention, Chem Rev, 2011; 111:6130-6185 https://doi.org/10.1021/cr200085w PMid:21910409 PMCid:PMC3196595
216. Jespersen SS, Stovgaard ES, Nielsen D, Christensen TD, Buhl ASK, Christensen IJ, Balslev E, Expression of secretory phospholipase A2 group IIa in breast cancer and correlation to prognosis in a cohort of advanced breast cancer patients, Appl Immunohistochem Mol Morphol, 2021; 29:E5-E9 https://doi.org/10.1097/PAI.0000000000000854 PMid:32217848
217. André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 2009; 350:2343-2351 https://doi.org/10.1056/NEJMoa032709 PMid:15175436
218. Zhang J, Wang L, Wang Z, Hu X, Wang B, Cao J, Lv F, Zhen C, Zhang S, Shao Z, A phase II trial of biweekly vinorelbine and oxaliplatin in second- or third-line metastatic triple-negative breast cancer, Cancer Biol Ther, 2015; 16:225-232 https://doi.org/10.4161/15384047.2014.986973 PMid:25648299 PMCid:PMC4622533
219. Garufi C, Nistico C, Brienza S, Vaccaro A, D'Ottavio A, Zappalà AR, Aschelter AM, Terzoli E, Single-agent oxaliplatin in pretreated advanced breast cancer patients: a phase II study, Ann Oncol, 2001; 12:179-182 https://doi.org/10.1023/A:1008386419047 PMid:11300320
220. Fei F, Chen C, Xue J, Di GH, Lu JS, Liu GY, Shao ZM, Wu J, Efficacy and safety of docetaxel combined with oxaliplatin as a neoadjuvant chemotherapy regimen for Chinese triple-negative local advanced breast cancer patients: a prospective, open, and unicentric phase II clinical trial, Am J Clin Oncol Cancer Clin Trials, 2013; 36:545-551 https://doi.org/10.1097/COC.0b013e31825d5317 PMid:22868245
221. Zelek L, Cottu P, Tubiana-Hulin M, Vannetzel JM, Chollet Ph, Misset JL, Chouaki N, Marty M, Gamelin E, Culine S, Dieras V, Mackenzie S, Spielmann M, Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients, J Clin Oncol, 2002; 20:2551-2558 https://doi.org/10.1200/JCO.2002.06.164 PMid:12011135
222. De Jonge MJA, Slingerland M, Loos WJ, Wiemer EAC, Burger H, Mathijssen RHJ, Kroep JR, Den Hollander MAG, Van Der Biessen D, Lam MH, Verweij J, Gelderblom H, Early cessation of the clinical development of LiPlaCis, a liposomal cisplatin formulation, Eur J Cancer, 2010; 46:3016-3021 https://doi.org/10.1016/j.ejca.2010.07.015 PMid:20801016
223. Pourhassan H, Clergeaud G, Hansen A, Østrem R, Fliedner F, Melander F, Nielsen O, O'Sullivan C, Kjær A, Andresen TL, Revisiting the use of sPLA2-sensitive liposomes in cancer therapy, J Contr Release, 2017; 261:163-173 https://doi.org/10.1016/j.jconrel.2017.06.024 PMid:28662900
224. Lassen U, Mau-Sørensen M, Buhl UH, Madsen MW, Balslev E, Pluim D, Schellens JHM, Knudsen S, Jensen PB, Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors, Cancer Res, 2016; 76:CT154-CT154 https://doi.org/10.1158/1538-7445.AM2016-CT154
225. Lassen UN, Knudsen S, Hertel PB, Kumler I, Nielsen D, Ejlertsen B, Mau-Sørensen MM, Brunner N, Buhl UH, Madsen MW, Buhl IK, Hansen A, Jensen T, Balslev E, Askaa J, Vestlev PM, Laenkholm AV, Jensen PB, Use of microRNA to identify stage IV breast cancer patients to be targeted with phospholipase A2 disrupted cisplatin carrying liposomes: an ongoing phase I trial, J Clin Oncol, 2014; 32:TPS1139-TPS1139 https://doi.org/10.1200/jco.2014.32.15_suppl.tps1139
226. Jakobsen EH, Nielsen D, Danoe H, Linnet S, Hansen J, Lassen UN, Balslev E, Glavicic V, Bogovic J, Knudsen S, Ejlertsen B, Knoop ASK, Buhl UH, Madsen MW, Buhl IK, Hansen A, Jensen T, Rasmussen A, Jensen PB, Langkjer ST, Liposomal cisplatin response prediction in heavily pretreated breast cancer patients: a multigene biomarker in a prospective phase 2 study, J Clin Oncol, 2018; 36:e13077 https://doi.org/10.1200/JCO.2018.36.15_suppl.e13077
Published
Abstract Display: 288 
PDF Downloads: 138 PDF Downloads: 110 How to Cite
Issue
Section
Copyright (c) 2026 Ajinkya Shrirang Holkar , Vinod Jagannathrao Mokale
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
How to Cite
.